Objectives: Cyclic decapeptide CGLIIQKNEC (CLT1) has been demonstrated to target fibronectin-fibrin complexes in the extracellular matrix of different tumors and tissue lesions. Although liver fibrosis is characterized by an increased amount of extracellular matrix consisting of fibril-forming collagens and matrix glycoconjugates such as fibronectin, we aimed to investigate the feasibility of detecting and characterizing liver fibrosis using CLT1 peptide-targeted nanoglobular contrast agent (Gd-P) with dynamic contrastenhanced magnetic resonance imaging in an experimental mouse model of liver fibrosis at 7 T. Materials and Methods: Gd-P, control peptide KAREC conjugated nanoglobular contrast agent (Gd-CP), and control nontargeting nanoglobular contrast agent (Gd-C) were synthesized. Male adult C57BL/6N mice (22Y25 g; N = 54) were prepared and were divided into fibrosis (n = 36) and normal (n = 18) groups. Liver fibrosis was induced in the fibrosis group through subcutaneous injection of 1:3 mixture of carbon tetrachloride (CCl 4 ) in olive oil at a dose of 4 KL/g of body weight twice a week for 8 weeks. Dynamic contrastenhanced MRI was performed in all animals. Dynamic contrast-enhanced magnetic resonance imaging was analyzed to yield postinjection $R 1 (t) maps for quantitative measurements. Histological analysis was also performed. Results: Differential enhancements were observed and characterized between the normal and fibrotic livers using Gd-P at 0.03 mmol/kg, when compared with nontargeted controls (Gd-CP and Gd-C). For Gd-P injection, both the peak and steady-state $R 1 of the normal livers were significantly lower than those after 4 and 8 weeks of CCl 4 dosing. Liver fibrogenesis with increased amount of fibronectin in the extracellular space in insulted livers were confirmed by histological observations. Conclusions: These results indicated that dynamic contrast-enhanced magnetic resonance imaging with CLT1 peptide-targeted nanoglobular contrast agent can detect and stage liver fibrosis by probing the accumulation of fibronectin in fibrotic livers.
L iver fibrosis is a common response to chronic liver injury, which is associated with high morbidity and mortality. 1 It may subsequently lead to cirrhosis with its consequences of portal hypertension, hepatocellular carcinoma, and liver failure. 2 Liver fibrosis is characterized by an increased amount of extracellular matrix consisting of fibril-forming collagens and matrix glycoconjugates such as fibronectin. 3Y5 Recently, fibronectin isoforms have been identified as a viable biomarker for liver fibrosis. 6 Hepatic fibrogenesis is a dynamic process with potential for regression. 7 Early diagnosis and quantification of liver fibrosis could facilitate early interventions and treatments, thus preventing its progression to cirrhosis. 8 Percutaneous liver biopsy has been considered the standard technique for diagnosis and staging of liver fibrosis. 9 However, liver biopsy is invasive in nature with potential complications, and its ability to assess fibrosis progression and treatment response longitudinally is limited by sampling error and interobserver variation. 10 Current techniques in assessing liver fibrosis such as routine liver function tests, serological tests of specific serum markers, and liver stiffness measurement using noninvasive ultrasound transient elastography are still under investigation.
2,11Y13 Development of noninvasive and reproducible alternatives for early diagnosis and staging of liver fibrosis and monitoring of disease progression or regression due to treatment effects is therefore desirable.
Conventional magnetic resonance imaging (MRI) has been used to assess liver fibrosis and cirrhosis; however, the anatomical analysis has been subjected to interobserver variability and limited in sensitivity and specificity.
14,15 Double-contrast MRI using both gadolinium chelates and superparamagnetic iron oxides (SPIOs) was suggested to provide synergistic effects in visualizing liver fibrosis directly based on hepatic texture alterations. 16, 17 Magnetic resonance elastography has shown promise in assessing liver fibrosis by measuring tissue stiffness. 18Y20 Alternatively, tagging MRI was proposed to measure the cardiac-induced motion and deformation in the liver to assess liver stiffness. 21 Apparent diffusion coefficient measured by diffusion-weighted imaging has been shown to decrease in fibrotic and cirrhotic liver as compared with normal liver. 22, 23 Changes in both the apparent diffusion coefficient and other diffusion properties were observed during the progression of liver fibrosis using diffusion tensor imaging and intravoxel incoherent motion analysis. 24, 25 Proton magnetic resonance spectroscopy was also demonstrated to provide a sensitive means to assess liver fibrosis through characterizing metabolic changes without the use of contrast agents. 26 More recently, longitudinal and transverse relaxation times as well as spin-lattice relaxation time in the rotating frame (T 1Q ) were shown to alter in fibrotic livers. 27Y30 However, the clinical utility of these advanced MRI techniques for staging liver fibrosis has yet to be established.
Molecular MRI aims to visualize and characterize biological processes at the molecular level in living organisms. 31 By coupling molecular activities with MR contrast agents specifically, visualization and monitoring of subcellular processes can be achieved. This technique usually involves specific labeled molecular probes. 32 Integrin-targeted ultrasmall SPIOs have been developed to probe the activated hepatic stellate cells in liver fibrosis of rats. 33 Study on molecular MRI of liver fibrosis is limited, mainly because of difficulty in searching for a specific biomarker and synthesizing the corresponding smart molecular probe. Recently, specific binding of a cyclic decapeptide CGLIIQKNEC (CLT1) to the fibronectin-fibrin complexes, formed by clotting of fibrin and fibronectin isoforms including oncofetal fibronectin and an alternatively spliced form of fibronectin, 34, 35 has been observed in the extracellular matrix of different tumors and tissue lesions.
36 CLT1 peptide-targeted nanoglobular MR contrast agent has been investigated for cancer molecular imaging with contrast-enhanced MRI.
37Y39 Specific binding of CLT1 in the tumor tissue after intravenous administration of the agent was also confirmed using fluorescent imaging technique. 36, 39 The targeted nanoglobular MR contrast agent demonstrated stronger tumor enhancement than a control nontargeted contrast agent did at a relatively low dose in a mouse tumor model, leading to potential applications in cancer detection and diagnosis, characterizing tumor angiogenesis and imaging wounds and atherosclerosis.
Fibrin-fibronectin complexes exist in a fibrotic liver because of the cross-linkage between fibrin/fibrinogen and fibronectin 40 ; therefore, they can serve as a specific molecular target for contrastenhanced MRI. In this study, we hypothesized that the increased amount of fibrin-fibronectin complexes in a fibrotic liver may be probed by CLT1 peptide-targeted nanoglobular contrast agent using contrast-enhanced molecular MRI. We aimed to investigate the feasibility of detecting and characterizing liver fibrosis using CLT1 peptide-targeted nanoglobular contrast agent with dynamic contrastenhanced MRI (DCE-MRI) in an experimental mouse model.
METHODS
All MRI measurements were acquired on a 7-T MRI scanner with a maximum gradient of 360 mT/m (70/16 PharmaScan; Bruker Biospin GmbH, Rheinstetten, Germany). A 38-mm quadrature resonator was used for radiofrequency transmission and reception. All animal experiments were approved by the local institutional animal ethics committee.
Synthesis and MR Characterization of Contrast Agents
CLT1 peptide-targeted nanoglobular contrast agent (Gd-P) was synthesized as described previously (Fig. 1) . 37 In brief, peptide CLT1 with a propargyl group at the N-terminus was synthesized using standard solid-phase peptide synthesis from Fmoc-protected amino acids on a 2-chlorotrityl chloride resin as described previously. 41 In brief, generation 3 (G3) poly-L-lysine dendrimers, known as nanoglobules, with an octa(3-aminopropyl)silsesquioxane cubic core were synthesized in good yield and purity using solution-phase peptide chemistry. 42, 43 Azido groups were introduced to the nanoglobules by reacting their surface amino groups with 3-[(2-azidoethylenoxy)-heptoa(2-ethylenoxy)]-propionic N-hydroxysuccinimide ester (Quanta BioDesign, Powell, OH). Dendrimeric gadolinium(III)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic monoamide acid (Gd-DOTA monoamide) conjugates, nanoglobular MR contrast agents, were synthesized using standard liquid-phase peptide synthesis chemistry. Gd-P was formed by conjugating CLT1 peptide to G3 nanoglobular contrast agent via ''click chemistry.'' The characterization and structural confirmation were carried out by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry on a Voyager DE-STR spectrometer (PerSeptive BioSystems, Framingham, MA) in linear mode with >-cyano-4-hydroxycinnamic acid as a matrix. Gadolinium(III) content in the contrast agent was determined by inductively coupled plasma optical emission spectroscopy (Optima 3100XL; Perkin-Elmer, Sheldon, CT). Approximately 3 peptides and 43 Gd-DOTA chelates were conjugated onto the surface of 1 G3 nanoglobular dendrimer (a total of 64 amine groups), as determined by amino acid analysis, and the sulfur content was measured by inductively coupled plasma optical emission spectroscopy.
To show that the targeting capability of Gd-P is not caused by its larger size, a control peptide KAREC with a propargyl group at the N-terminus was prepared using standard solid-phase peptide synthesis (m/z, [M+H] + : 919.45; observed: 919.63). Note that peptide KAREC has been reported to show no binding to fibrin-fibronectin complexes. 36 Similarly, control peptide KAREC conjugated nanoglobular contrast agent (Gd-CP) was synthesized after the procedure of Gd-P synthesis. In this study, peptide-free G3 nanoglobular Gd-DOTA monoamide conjugate was also prepared as the control nontargeting nanoglobular contrast agent (Gd-C). Longitudinal relaxivity (r 1 ) and transverse relaxivity (r 2 ) were determined for Gd-P, Gd-CP, and Gd-C suspensions. In brief, randomly uniform suspensions were prepared for nanoglobular contrast agent concentrations of 5 and 10 mM with the addition of saline. They were then placed in separate 2-mL cylindrical phantom tubes for longitudinal relaxation rate (R 1 ) and transverse relaxation rate (R 2 ) mapping. R 1 maps of nanoglobular contrast agents were acquired with a series of spin-echo images with varying pulse repetition times (TRs). The parameters were as follows: TRs, 40 
Liver Fibrosis Model
Male adult C57BL/6N mice (22Y25 g; N = 54) were prepared and were divided into fibrosis (n = 36) and normal (n = 18) groups. The overall schedule of the experiment is shown in Figure 2 . Liver fibrosis was induced in the fibrosis group through subcutaneous injection of 1:3 mixture of carbon tetrachloride (CCl 4 ) in olive oil at a dose of 4 KL/g of body weight twice a week for 8 weeks. 24, 26, 44 Intermittent administration of CCl 4 has been widely used to experimentally induce liver fibrosis in rodents by evoking a marked infiltration of inflammatory cells, thus mimicking the changes in chronic viral hepatitisYassociated fibrosis in many ways. 45, 46 The twice-weekly dosing can induce established hepatic fibrosis and cirrhosis after 4 and 8 weeks of CCl 4 administration, respectively, in rodents. 44 This well-controlled CCl 4 -induced liver fibrosis model allows the study of a homogeneous population of liver fibrosis. 25, 29 Dynamic contrast-enhanced MRI was performed in the CCl 4 -insulted animals at 4 and 8 weeks after the start of CCl 4 administration. The normal group was untreated and served as a control.
In Vivo MRI Experiments
Before each imaging session, each mouse was anesthetized with isoflurane/air at 3% for induction and 1.5% for maintenance via a nose cone. Femoral vein catheterization was performed using a 1-m long tube (MTV-1; Braintree Scientific Inc, Braintree, MA) connected to a 28-gauge needle. The dead space in the catheter was about 0.2 mL. During the imaging, animals were anesthetized with isoflurane/air using 1.0% to 1.5% via a nose cone with respiratory monitoring. Body temperature was maintained at about 36.5-C by circulating warm water in a heating pad. Each mouse was fixed in a supine position. A reference phantom containing phosphate-buffered saline was placed next to each animal. For each imaging session, anatomical images, preinjection T 1 measurements, DCE-MRI, and maximum intensity projection images before and after contrast injection were obtained.
High-resolution anatomical T 1 -weighted images were acquired with 2-dimensional fast spin-echo sequence using the fol- ; NEX, 4; and temporal resolution, 20 seconds. For each imaging session, 0.1 mL of contrast agent (0.03 mmol Gd/kg) was slowly injected (È2 seconds) into the catheter at a rate of 3 mL/min about 6 minutes after the start of dynamic scanning. A 0.4 mL of saline flush (È8 seconds) was administered immediately thereafter to drive the contrast agent from the catheter into the femoral vein. T 1 -weighted maximum intensity projection images were also acquired using 3-dimensional FLASH sequence before and after the injection of the contrast agents. The parameters were as follows: TR, 12. 
Data and Statistical Analysis of DCE-MRI
Dynamic contrast-enhanced MRI was analyzed to yield postinjection $R 1 (t) maps for quantitative measurements. In detail, DCE images were first coregistered using automated image registration (AIR5.2.5). 47 Normalized liver signal intensity was calculated as the ratio of signal intensity of liver to that of the phantom and was averaged over slices in each animal. Assuming that negligible T 2 effects from the injected contrast agents due to the short TE and low dose were used, peak $R 1 maps were computed on a pixel-by-pixel basis 48 over 3 slices as follows:
where S pre is the average intensity of 15 preinjection images and S(t) is the intensity of postinjection image with maximum contrast enhancement. Similarly, steady-state $R 1 maps were obtained using S(t) as the average intensity of 90 postinjection images at the end of the dynamic scanning. To estimate liver peak and steady-state $R 1 in each mouse, a large region of interest (ROI) was manually drawn in a homogeneous liver region on the basis of the high-resolution fast spin-echo images. One-way analysis of variance with the Tukey multiple comparison tests was used to compare differences in peak and steady-state $R 1 values in different groups, with P G 0.05 considered as statistically significant.
Histology
After the MR examination following the 4 weeks of CCl 4 administration, 6 of the18 animals were killed for histological examination. Furthermore, 6 of the 18 animals were killed after the MR examination following the 8 weeks of CCl 4 insult as shown in Figure 2 . Six normal animals were killed as a control. Liver specimens were fixed in formalin, embedded in paraffin, sectioned, and FIGURE 2. Schedule of carbon tetrachloride (CCl 4 ) twice-weekly administration for induction of liver fibrosis in male adult C57BL/6N mice, DCE-MRI, and histology. examined through light microscopy after the standard hematoxylineosin (H&E) staining and the Masson trichrome staining for collagen deposition. 49, 50 Immunohistochemical technique was used to detect and depict fibronectin. In brief, the liver sections were heated in antigen retrieval solution (0.01-M citrate buffer, pH 6.0; Sigma, St. Louis, MO) and then incubated with primary antifibronectin antibody (Sigma, St. Louis, MO) diluted to 1:400 with 0.01-M phosphate-buffered saline (pH 7.4) overnight at room temperature. After washing with phosphate buffer solution, the sections were incubated with biotinylated secondary antibody and a horseradish peroxidase-streptavidin complex for 1 hour each. Tissue samples were then colorized with 3,3 ¶-diaminobenzidine substrate, counterstained with hematoxylin and mounted. 37 
RESULTS
The sizes of Gd-P, Gd-CP, and Gd-C were about 6.2, 6.3, and 5.8 nm, respectively, as determined by dynamic light scattering analysis. At 7 T, $R 1 and $R 2 values of the nanoglobular contrast agent at 5 and 10 mM were plotted in Figure 3 . Note that the r 1 relaxivities of Gd-P, Gd-CP, and Gd-C were 6.79 (0.40), 6.15 (0.05), and 6.25 (0.09) mM j1 s j1 , respectively, whereas the r 2 relaxivities of Gd-P, Gd-CP, and Gd-C were 19 , respectively. Contrast enhancements were consistently observed in all mice studied for Gd-P, Gd-CP, and Gd-C. No apparent adverse effects were observed in those mice during and after the imaging sessions. Figure 4 illustrates the liver images typically observed during Gd-P, Gd-CP, and Gd-C injections (0.1 mL of 0.03 mmol/kg) for mice after a 4-week CCl 4 dosing. For the Gd-P injection, Figure 4A shows one of the preinjection FLASH T 1 -weighted images, the FLASH T 1 -weighted image with the maximum contrast enhancement at the È4-minute postinjection, and the FLASH T 1 -weighted image at the È54-minute postinjection. Figure 4B depicts the typical T 1 -weighted signal time courses during the Gd-P injection with ROIs indicated in Figure 4A . Two ROIs were selected from 1 homogeneous liver region (LV) and the region covering inferior vena cava (IVC) regions. For the Gd-CP injection, Figure 4C shows one of the preinjection FLASH T 1 -weighted images, the FLASH T 1 -weighted image with the maximum contrast enhancement at the È4-minute postinjection, and the FLASH T 1 -weighted image at the È54-minute postinjection. Similarly, Figure 4D depicts the typical T 1 -weighted signal time courses during the Gd-CP injection with ROIs indicated in Figure 4C . For the Gd-C injection, Figure 4E shows one of the preinjection FLASH T 1 -weighted images, the FLASH T 1 -weighted image with the maximum contrast enhancement at the È4-minute postinjection, and the FLASH T 1 -weighted image at the È54-minute postinjection. Similarly, Figure 4F depicts the typical T 1 -weighted signal time courses during the Gd-C injection with ROIs indicated in Figure 4E . Figure 5 illustrates the corresponding images typically observed during the Gd-P, Gd-CP, and Gd-C injections (0.1 mL of 0.03 mmol/kg) for mice after the 8-week CCl 4 dosing, whereas Figure 6 illustrates the corresponding images for the normal mice.
Strong signal enhancements were observed in the liver parenchyma at the postinjection of Gd-P, when compared with Gd-CP and Gd-C. Note the similar signal time courses observed in LV and IVC (Figs. 4C, E; 5C, E; and 6C, E) for the Gd-CP and Gd-C injections. Gd-P consistently showed higher contrast enhancement than did Gd-CP and Gd-C in the liver at the postinjection steady state. Furthermore, contrast enhancement by Gd-P persisted during the dynamic scanning, whereas enhancements by Gd-CP and Gd-C decreased and vanished rapidly after the maximum enhancement. Figure 7 summarizes the peak and steady-state $R 1 measurements for all animals studied with Gd-P. ; P G 0.01). No significant difference in the peak and steady-state $R 1 was observed between the different groups of animals for the Gd-CP and Gd-C injections. Note that injection rate of 3 mL/min was kept constant for all the animals studied. For all contrast agents, strong contrast enhancement was observed in the urinary bladder 1 hour after the injection (data not shown). (Fig. 8A) , collagen deposition and intracellular fat vacuoles were consistently observed in the livers with CCl 4 insult (Fig. 8B and C) . Similar histological findings were observed in all liver samples collected, and they were largely consistent with those from the earlier studies of CCl 4 -induced liver fibrosis in rodent models. 51 The histological observations of collagen deposition in the liver samples collected confirmed the liver fibrogenesis in the animals studied. Figure 8 also shows typical immunohistochemical staining of fibronectin for the normal liver and the livers at 4 and 8 weeks after the CCl 4 insult. Compared with the normal liver (Fig. 8A) , the insulted liver showed increased amount of fibronectin in the extracellular space as revealed by brown deposits after staining with an antifibronectin antibody (Fig. 8B and C) . These histological findings were consistent with those observed in previous hepatic fibrosis immunohistochemical studies. 
DISCUSSIONS
The histological observations revealed the collagen deposition and thus confirmed liver fibrogenesis in the animals studied. For all the animals studied, the higher contrast enhancement of Gd-P compared with Gd-CP and Gd-C in the liver at the postinjection steady state suggested the specific binding of Gd-P to the liver, consequently leading to strong and prolonged contrast enhancement. Note the existence of fibronectin in the normal liver due to its function of producing plasma fibronectin. 40 In contrast, nontargeting effects of Gd-CP and Gd-C were supported by their vanishing enhancement after the maximum enhancement for all animals. These results were consistent with our earlier studies of the same contrast agents in mouse cancer models. 37, 39 Both the peak and steady-state $R 1 after Gd-P were higher in the fibrotic livers than in the normal livers, which is likely because of the increased amount of accumulated Gd-P in consequence of raised quantity of fibronectin in fibrotic livers. From the quantitative peak and steady-state $R 1 analysis, the fibrotic livers could be readily distinguished from the normal livers after the injection of Gd-P. Our current findings demonstrated the feasibility of detection of liver fibrosis after injection of CLT1 peptidetargeted nanoglobular contrast agent through molecular imaging of fibronectin.
In this study, CLT1 peptide-targeted nanoglobular contrast agent was successfully demonstrated for the first time in detecting liver fibrosis through molecular MRI. Peptide-targeted nanoglobular contrast agent (Gd-P) and nontargeted controls (Gd-CP and Gd-C) were examined for their contrast enhancement effects through dynamic liver imaging at 7 T. The strong and prolonged enhancement likely resulted from the increased binding of CLT1 peptide-targeted nanoglobular contrast agent to the increased fibrin-fibronectin complexes in the fibrotic liver. Peak and steady-state $R 1 induced by Gd-P (0.1 mL of 0.03 mmol/kg) for the fibrotic livers were higher than that of the normal livers, whereas values of peak and steady-state $R 1 upon the Gd-CP and Gd-C injections were comparable in all animals. These results suggested the potential of DCE-MRI with Gd-P to detect and characterize liver fibrosis.
The relaxivities r 1 and r 2 of the nanoglobular contrast agents increased with increasing sizes. The relaxivities of Gd-P and Gd-CP were slightly higher than that of Gd-C. The relaxivities of the nanoglobular contrast agents 37, 39 were similar to those of other reported dendrimeric Gd-DOTA-monoamide conjugates (r 1 /r 2 , 11/13 mM j1 s j1 ). 53, 54 Dynamic light scattering analysis showed that the nanoglobular contrast agents had a particle size of 5.8 to 6.2 nm. Considering the renal filtration threshold of 8.0 nm, 55 the small sizes of the nanoglobular FIGURE 6. Corresponding images from the normal mouse. During the Gd-P injection: A, The preinjection FLASH T 1 -weighted image, the FLASH T 1 -weighted image with the maximum contrast enhancement at the È4-minute postinjection, and the FLASH T 1 -weighted image at the È54-minute postinjection. B, T 1 -weighted signal time courses in different regions during the Gd-P injection. C to F,contrast agents allow rapid excretion after injection. 37 The T 1 -weighted maximum intensity projection images (data not shown) also confirmed that the unbound nanoglobular contrast agents were gradually excreted through renal filtration and accumulated in the urinary bladder.
The synthesized G3 dendrimer exhibits a globular morphology and relatively compact and rigid 3-dimensional structure. The high functionality for conjugation is suitable for preparation of targeted contrast agents with high peptide to gadolinium chelate ratios. The contrast agent dosage used in the current study (0.03 mmol/kg) was lower than that used in clinical contrast-enhanced MRI (0.1 mmol/kg). 56 However, its large size and high number of conjugated CLT1 peptides resulted in slow excretion and might limit its future clinical application. 37 By optimizing the dosage, peptide to gadolinium chelate ratios, and size, it is possible to enhance the sensitivity and specificity for future clinical applications. The study on molecular MRI of liver fibrosis is limited so far. Recently, integrin-targeted ultrasmall SPIOs have been developed to probe the activated hepatic stellate cells in liver fibrosis of rats. 33 In liver fibrosis, activated hepatic stellate cells would engulf integrintargeted ultrasmall SPIOs for negative signal enhancements. In this study, we presented an alternative approach to target molecular probes in liver fibrosis for positive signal enhancements through identifying fibrin-fibronectin complexes as biomarkers in fibrotic liver. Molecular MRI is therefore feasible if one can identify specific molecular probes in the visualization and monitoring of subcellular processes. The proposed Gd-based contrast agent offers the advantage of positive contrast enhancement and direct molecular targeting. FIGURE 7. In vivo measurements of peak and steady-state $R 1 for all animals studied with Gd-P. One-way analysis of variance with the Tukey multiple comparison test was performed with * for P G 0.05, ** for P G 0.01, and n.s. for insignificance. Future studies with fibrin-targeting contrast agents may also be sought.
57Y59
One potential limitation of the current study is the difference in the development and progression of liver fibrosis in the CCl 4 -intoxication fibrosis model when compared with those in humans due to different etiology of the disease. In particular, the repetitive dosing of CCl 4 in animals can induce fibrosis development within weeks, whereas the development of fibrosis in patients with liver diseases is more gradual and may take several months or years depending on the underlying causes. Despite different etiology, the underlying pathophysiologic processes of fibrogenesis (eg, inflammatory cell infiltration, cell necrosis, fibroblast proliferation, pronounced extracellular matrix/collagen deposition, and potential progression to cirrhosis) are largely similar. 60, 61 In addition, the current histological finding of collagen deposition and increased fibronectin in the experimental fibrosis model was in accordance with those reported in patients with liver fibrosis, 3Y5 suggesting that the targeting capability of Gd-P over fibrotic livers in clinical settings would be similar. The other limitation in the current study is the lack of independent method to directly validate the MRI results observed. Other quantitative methodologies, including but not limited to fluorescent labeling of contrast agents with histological correlation and absolute gadolinium contents determination with inductively coupled plasma technique, are currently under investigation at our laboratory to confirm the specific binding of Gd-P in liver fibrosis.
In conclusion, CLT1 peptide-targeted nanoglobular contrast agent was successfully demonstrated for the first time to detect liver fibrosis through molecular imaging of fibronectin. Considerable contrast enhancements were observed and characterized in the normal and fibrotic livers using CLT1 peptide-targeted nanoglobular contrast agent at a relative low dose when compared with the nontargeted control. Differential enhancements were demonstrated between the normal and fibrotic livers after the CLT1 peptide-targeted nanoglobular contrast agent injection. These results indicated that DCE-MRI with CLT1 peptide-targeted nanoglobular contrast agent could detect and stage liver fibrosis by probing the accumulation of fibronectin in fibrotic livers.
